The Fight Against COVID19
23.81k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
|---|---|---|---|---|
| The Fight Against COVID19 | -0.52% | - | - | - |
| ^GSPC | +0.02% | -2.81% | +24.56% | +5353.36% |
14 Symbols
| Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 148.53 | -1.03 | -0.69% | 4:00 p.m. EDT | 9.60M | 7.63M | 357.92B |
| ABBV | AbbVie Inc. | 167.8 | -1.74 | -1.03% | 4:00 p.m. EDT | 3.97M | 5.62M | 297.12B |
| PFE | Pfizer Inc. | 26.27 | -0.05 | -0.19% | 4:00 p.m. EDT | 23.38M | 42.21M | 148.75B |
| SNY | Sanofi | 46.61 | -1.08 | -2.26% | 4:00 p.m. EDT | 1.66M | 1.93M | 118.15B |
| REGN | Regeneron Pharmaceuticals, Inc. | 906.54 | -0.78 | -0.09% | 4:00 p.m. EDT | 373.47k | 464.59k | 99.50B |
| GILD | Gilead Sciences, Inc. | 67.08 | +0.05 | +0.07% | 4:00 p.m. EDT | 8.26M | 7.19M | 83.65B |
| GSK | GSK plc | 40.86 | -0.38 | -0.92% | 4:00 p.m. EDT | 1.66M | 3.48M | 83.48B |
| TAK | Takeda Pharmaceutical Company Limited | 13.23 | -0.15 | -1.12% | 4:00 p.m. EDT | 924.52k | 1.83M | 41.92B |
| MRNA | Moderna, Inc. | 108.85 | +0.96 | +0.89% | 4:00 p.m. EDT | 3.39M | 3.78M | 41.68B |
| BNTX | BioNTech SE | 88.09 | -0.40 | -0.45% | 4:00 p.m. EDT | 280.56k | 605.02k | 21.23B |
| VIR | Vir Biotechnology, Inc. | 8.04 | -0.09 | -1.11% | 4:00 p.m. EDT | 738.08k | 1.05M | 1.09B |
| NVAX | Novavax, Inc. | 4.15 | -0.04 | -0.95% | 4:00 p.m. EDT | 2.43M | 7.22M | 580.80M |
| INO | Inovio Pharmaceuticals, Inc. | 10.16 | -0.21 | -2.03% | 4:00 p.m. EDT | 246.77k | 484.32k | 263.21M |
GlobeNewswirePress Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performa
Business WirePfizer Declares Second-Quarter 2024 Dividend
NEW YORK, April 24, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024. The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer.
ZacksTop Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
